News

Researchers in GE’s nanotechnology lab have developed promising nanoparticle based imaging agents that could increase imaging resolution and sensitivity. The ability to see and target disease with higher

The offer is valued at approximately $4.7 billion, to equity holders of ImClone, other than Bristol-Myers Squibb. Bristol-Myers Squibb currently owns approximately 16.6% of all outstanding shares of

These contracts are in addition to the December 1, 2006 announcement for the award of over $230 million for Crucell’s Quinvaxem and Hepavax-Gene vaccines, and the new contracts

The European Medicines Agency’s orphan drug designation is reserved for new therapies being developed to treat life-threatening or chronically debilitating diseases or conditions that are relatively rare in

As a result of the approval, Orexo will receive a milestone payment of $1 million. This authorization will enable ProStrakan to complete UK pricing negotiations and launch planning

One of Gemin X’s lead pipeline programs, obatoclax is an oncology treatment based on programmed cell death, or apoptosis, and has the potential to be a first-in-class pan

Under the terms of the assignment, Arisyn will assume the intellectual property portfolio. In return, UAF Technologies and Research (UTR) will receive a cash assignment fee, cash payments

The Guard Study (MGuard) in acute myocardial infarction study is designed to evaluate the safety and efficacy of MGuard in patients suffering from ST-segment elevation myocardial infarction. The

With FDA approval of the abbreviated new drug application (ANDA), which was filed by the company’s Mallinckrodt subsidiary, Covidien’s generic product is now available for customers in the